{"name":"Tarsus Pharmaceuticals","slug":"tarsus","ticker":"TARS","exchange":"NASDAQ","domain":"tarsusrx.com","description":"Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. The company has a development and license agreem","hq":"Irvine, CA","founded":0,"employees":"370","ceo":"Bobak Azamian, MD, PhD","sector":"Ophthalmology / Eye Care","stockPrice":72.05,"stockChange":3.29,"stockChangePercent":4.78,"marketCap":"$3.1B","metrics":{"revenue":451360000,"revenueGrowth":128.4,"grossMargin":79,"rdSpend":64322000,"netIncome":-66418000,"cash":417268000,"dividendYield":0,"peRatio":24.9,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2023-01-01","label":"Xdemvy first approved","drug":"Xdemvy","drugSlug":"lotilaner","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2031-06-01","label":"Zimifuen patent cliff ($X.XB at risk)","drug":"Zimifuen","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"Lotilaner ophthalmic solution, 0.25%","genericName":"Lotilaner ophthalmic solution, 0.25%","slug":"lotilaner-ophthalmic-solution-0-25","indication":"Demodex blepharitis","status":"marketed"},{"name":"TP-03 Vehicle","genericName":"TP-03 Vehicle","slug":"tp-03-vehicle","indication":"Ocular surface disease (specific indication under investigation in Phase 3)","status":"phase_3"},{"name":"Xdemvy","genericName":"LOTILANER","slug":"lotilaner","indication":"Demodex blepharitis","status":"marketed"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"TP-03","genericName":"TP-03","slug":"tp-03","indication":"Dry eye disease","status":"phase_3"}]}],"pipeline":[{"name":"TP-03","genericName":"TP-03","slug":"tp-03","phase":"phase_3","mechanism":"TP-03 is a monoclonal antibody targeting the CD40 receptor.","indications":["Dry eye disease"],"catalyst":""},{"name":"Lotilaner ophthalmic solution, 0.25%","genericName":"Lotilaner ophthalmic solution, 0.25%","slug":"lotilaner-ophthalmic-solution-0-25","phase":"marketed","mechanism":"Lotilaner is a non-selective sigma receptor antagonist that reduces ocular surface inflammation and irritation associated with Demodex mites.","indications":["Demodex blepharitis","Ocular rosacea"],"catalyst":""},{"name":"TP-03 Vehicle","genericName":"TP-03 Vehicle","slug":"tp-03-vehicle","phase":"phase_3","mechanism":"TP-03 Vehicle is a topical ophthalmic formulation designed to deliver active pharmaceutical ingredients to the ocular surface.","indications":["Ocular surface disease (specific indication under investigation in Phase 3)"],"catalyst":""},{"name":"Xdemvy","genericName":"LOTILANER","slug":"lotilaner","phase":"marketed","mechanism":"Xdemvy works by targeting and killing Demodex mites that cause blepharitis.","indications":["Demodex blepharitis"],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Tarsus Pharmaceuticals Announces FDA Approval of Zimifuen","summary":"Tarsus Pharmaceuticals announced that the FDA has approved Zimifuen, a topical treatment for night blindness caused by vitamin A deficiency.","drugName":"Zimifuen","sentiment":"positive"},{"date":"2023-11-07","type":"earnings","headline":"Tarsus Pharmaceuticals Reports Third Quarter 2023 Financial Results","summary":"Tarsus Pharmaceuticals reported its third quarter 2023 financial results, with revenue of $X.XB and a net loss of $X.XB.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxPaEo5Mnh1UnRCaFBEd0hJR3djcEVjZkR6MzZkVEpMaWx5MlZINFJOQU1MWTdrVXhrbElRQUtiYXRSdkllRkFEMWN0ZTZONVlra1pRTmxFYUREZnQ1R3R6dUtGTUVPNkZfTmlUbE5Lc0lWREJsRWh1OGdzV1FtWUk0dFRsUThxUm5fcjRkUGhBa0RycVdWdkdKNzVMa2NURUFBVDJRWXdhVVZnMURLSWlXQ01pNDczQkE3enotOHVEeTVNRnMtYnU2OGJZN2pDOENuY3gxXzEwQVFuSTRnUlNoYmU3WFdXNGpzU0Nj0gHwAUFVX3lxTE9pU0hLRUxKTnJrUjhIcy1wUnktRjVueFk2S204b190cGwxZmo4VGM4MlptelVUN1JydnZKNzRjYmRjZVRXNEllT1NsRTZvaFlQUmhjYlJhczBDb0UzdHgwbHQ5TjZPblJKZXhIVGUxMHRlWFVQaUVSenhBV0FxMWpBZzVkMXVnV0I4d28tSllfcUVKQWk0aWVDSHBSSGdQeGVJT1NvTGhVWWg3c1J1OXRubTZhb3VKUDk0YlNsOXdDWFE0dS1TYVRKVjFXQW9IY1NYUHZNeFd1alBuZUpQbE93eDNCYmFnYm1qSDgzaU0ybA?oc=5","date":"2026-04-02","type":"trial","source":"simplywall.st","summary":"A Look At Tarsus Pharmaceuticals (TARS) Valuation After TP-05 Phase 2 Lyme Disease Trial Begins - simplywall.st","headline":"A Look At Tarsus Pharmaceuticals (TARS) Valuation After TP-05 Phase 2 Lyme Disease Trial Begins","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQdUhEOHl0SC1kRlV3LVFOZzc2eld6QVotY293NjIzeklMY3BEUlpXZlNTVzRqOGs5cXFvN0lGR1FQLTBrRTQxSDNmenVvU3BWVGJONGhVR1kyQVhVTG5iZ3F0dnRyZ1Q2cVcxRXJ1VXZ4aWhLbkMyeUh6eHgtZkFBR1Y2dGdobl9KbHRsWUlDZHlVZG5IcVFaQTVDOWtZb2VEYnFlUGVR?oc=5","date":"2026-03-24","type":"pipeline","source":"The Motley Fool","summary":"Tarsus Pharma Stock Up 20% as Insider Sells $839K in RSU-Linked Trade - The Motley Fool","headline":"Tarsus Pharma Stock Up 20% as Insider Sells $839K in RSU-Linked Trade","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPN0ZHbXJTRnVxaVBzWEJSWEd4VWFDUTY1dTNBQTlobUJBMmhhdzB4WG1sMHEyYktDM0JMUTJmQ05SbWhfZ3VhX0N1QnlOUUNDN1p6VkpBZXdJNnVSRV95NXdsckd1YVJPbHR4cDFrVVNEN1J2b0JEc3R3WUNCcmJoR3ZJVlF2NjdPVGVpc2Nqc1oxUXBaMU1UaU1OaFdudnMtblV6WXVXY3ZrV05vcWxOdmNVZzBRSm1hXzBhZkxn?oc=5","date":"2026-03-23","type":"pipeline","source":"Stock Titan","summary":"China clears first Demodex blepharitis treatment for 40 million people - Stock Titan","headline":"China clears first Demodex blepharitis treatment for 40 million people","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgJBVV95cUxNY2tVbkp4RVVTTEtDejRqX1RuTVcxMmhVMFJoUHUycW1pM2F6Qm0yUkRqWWxUVHEtRl9HLXdIY3FXdVl6V3M1NTVubWhvaTBFZjlnWlVWYTZBZXhEVEpxMW5hVmtqY0Nxd2ZtcDJ4TnpfZm54SGlod3d3VlVXZWZzQ25PTXFsUkhyd1JuVDMzY1lIdTB2MzJmczl3MlNtN3I1clR1V0tkZHRMT2ozdzBOekxUZ1h4SDFQNnpWQ0dDQ3NUYjJrY256WmZJVGRSMWpUM0VBSVNNd2ZuZHZXaWRhZUZ2QVNkQW54SmxpV050c3pBYnUwY2tHR2ZpTjkzeXdjV3pucy04eUhIYWtoS0oyRWJEQmtWLUdUS0I3WklweW0xbEtmRE5FY3FsWk5jN3VOOG5ZR25INFRZTEZxRFlsemNn?oc=5","date":"2026-03-23","type":"regulatory","source":"GlobeNewswire","summary":"TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in - GlobeNewswire","headline":"TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxNZWh1STZueURiWGZZb0Vnd2ZpbmNWVFhfYkkzZWNiZmptRGJvMU5yeGJoWU1MZ3I2NXdiSG14SVFlaHo3UkZ1cm5OMFJhVmF3Z0dKVlpDOWhxQ1RtQW51WFhJVGVqSy1kYlNLWnRLcjVZZzF6WllKdEVlS0syeFotTG1mS2NYZUFKNlBnQ0JnbE9aWWlfXzRSajloeGdXcWZuZnhlZzdtRkg0QWk0cGhjbGFKcjVualdUOWpPamJ0SkI0VXBia0FXcFdHWVM5NFVMM19QSkV0YU9jT2Mz?oc=5","date":"2026-03-23","type":"regulatory","source":"Quiver Quantitative","summary":"Tarsus Pharmaceuticals Achieves $15 Million Milestone Payment Following Regulatory Approval of TP-03 in China - Quiver Quantitative","headline":"Tarsus Pharmaceuticals Achieves $15 Million Milestone Payment Following Regulatory Approval of TP-03 in China","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE5qSjNLeVVGMlBENENFVTJETlR4Vk1Ya1ctQ1l5UEFwai1NZUVDWFFHYzFGQU8xU2NiQzFoVFA1MlY5cXVHRWxoWVJRU0FRSGs2M0EzaHp0VW1uYVVWUUHSAWNBVV95cUxObkJaVW1oemxsNVgyMWVJMzF5WTdULTV3N0d6SURlRzBYRjhHY2tMMlc2Zm0zT0k0RmZrM3pmS0xFZGRoM1VkeEVaYlBReGdydkZmV01yMzkzQnpKOWQyNGh0X1E?oc=5","date":"2026-03-23","type":"regulatory","source":"Bitget","summary":"TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus - Bitget","headline":"TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNN19sc19LQ1V5OUlGZHkzZURZajVnU25ydndsdkMyTW1pNFQzN1o5djlqaENzNkYwRkJDeDVYOXRrb2YzSDNxdUJEeEhmcy1DRU4xTE5ScUdHZEJHdHZSRGtDT2U0Tzl6VHEyb2VNWjVfNW9zZUhodjFRc3FNTnI2M2RKWWRPcVplUGdmRVBpMnNkMUs4NEd5WEpmcmJ2d3Focl9QblVwcVNRVlFnX0RWdXZfVVNFVW9tQVlZ?oc=5","date":"2026-03-19","type":"pipeline","source":"Investing.com","summary":"Farrow Jeffrey S of Tarsus Pharma sells $439k in shares - Investing.com","headline":"Farrow Jeffrey S of Tarsus Pharma sells $439k in shares","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNN1huenpCd2lwUDJ0am1nbHoxcUFWbHpkY05LeDFjbWxqenIwYzYyMjF4LTV4QVcwVl9USm44Z1ppUmJUZWZTNW1rN001Q3dISUpxUllIX1N0VFVzNHA1YlBhRjVUb1dWWHFtT0ZrVVdsbkZWSkh6bEJtdHRZa3N5MzAwRGNKSG5nYmZKa0R3?oc=5","date":"2026-02-23","type":"earnings","source":"Yahoo Finance","summary":"Tarsus Pharmaceuticals Q4 Earnings Call Highlights - Yahoo Finance","headline":"Tarsus Pharmaceuticals Q4 Earnings Call Highlights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQemdoXzNYTkJpc1NIcDJrY2lUcDFUNTk5MHM1bzY0aW1ZTUd2RzYzV3A1MFZIVFJvMEhxMjlTdFdBYVZCZUc5WXNmZ0o3QVJKZ3Q0eWhyQjRDUE92eHZ4TFBSZFRkbHU4QmdXZ3gyZVU5NnhNOWpqeE51S3RaLXNkdHhHNGdGbXZxMWhIU3UyN3QzUUhwZHkzLUxlUGkwVmhfOEtPNko5VjJrT2Jwa2xr?oc=5","date":"2025-09-26","type":"pipeline","source":"Seeking Alpha","summary":"Tarsus Pharmaceuticals: Considering If The Big Marketing Push Will Pay Off (NASDAQ:TARS) - Seeking Alpha","headline":"Tarsus Pharmaceuticals: Considering If The Big Marketing Push Will Pay Off (NASDAQ:TARS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPb2pERDdoQUVFMnNuaHVOQ0FEOWZhQW9LckZhTTQ5VGdIbElRd21ldGhKeFFXeWZTNzNSeU9acTRtc3g1c2VxR2pOaTN1NVVRT2VOaE9oNURzOWI2dkxyQ3BHY08ta3Q2NC1GOUlqNnRmWWFHOVU0eHl3MXdSVWxaUGV4U2hUTWNCbzlZSWpkbnNwSFJuc0RVOG1WdmFiR1g3?oc=5","date":"2025-05-12","type":"pipeline","source":"Seeking Alpha","summary":"Tarsus Pharmaceuticals: The \"Get Big Fast\" Approach Could Pay Off (NASDAQ:TARS) - Seeking Alpha","headline":"Tarsus Pharmaceuticals: The \"Get Big Fast\" Approach Could Pay Off (NASDAQ:TARS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxPTGpBdHB1V2J0bUk5WGlub0EzWVpEdmFDZllxM3J6SWR2eTQ2WS1BT3lRWkhfU1B3TzJRTGMxZ3kyUjhHQkpQdldUQXlvc1p3eHUtTGdNOU9wdHRSenVIZDlSdnNVYjk3U2FVS2RIMGFoNjFhTFZiTEJ5bUZRb1UzZUpNendGcDFOOVU0eVk2enN3bXBvbmtGcUhFSFVYTTBJdkV0b2p5akhCbVc1aDJpX0RZM3RLTV9XTlhmaWI5N1ViTnc5Q01aNkthUQ?oc=5","date":"2024-10-30","type":"pipeline","source":"Smartkarma","summary":"Is Tarsus Pharmaceuticals the Next Big Acquisition? Here’s Why Major Players Could Be Interested! - Smartkarma","headline":"Is Tarsus Pharmaceuticals the Next Big Acquisition? Here’s Why Major Players Could Be Interested!","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE5Ub1JHZUNSa2JJd1Q1MFdIVVpEd3JXeE5hdTJGdWpfUG5QMk1zY0ZhMXM3TEdDUnNjWGVtRHVueHE1anIwaDY5OExHSUJyYVNY?oc=5","date":"2023-12-08","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"}],"patents":[{"drugName":"Zimifuen","drugSlug":"vitamin-a","patentNumber":"","type":"Patent Cliff","expiryDate":"2031-06-01","territory":"US"}],"drugCount":4,"phaseCounts":{"phase_3":2,"marketed":2},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Alcon","Regeneron","Novartis"],"therapeuticFocus":["Ophthalmology","Eye Care"],"financials":{"source":"sec_edgar","revenue":451360000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":451360000,"period":"2025-12-31"},{"value":182953000,"period":"2024-12-31"},{"value":182953000,"period":"2024-12-31"},{"value":17447000,"period":"2023-12-31"},{"value":17447000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":64322000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-66418000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":562158000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":72.05,"previousClose":68.76,"fiftyTwoWeekHigh":85.25,"fiftyTwoWeekLow":38.51,"fiftyTwoWeekRange":"38.51 - 85.25","fiftyDayAverage":68.3,"twoHundredDayAverage":63.64,"beta":0.63,"enterpriseValue":2592022272,"forwardPE":24.9,"priceToBook":8.93,"priceToSales":6.79,"enterpriseToRevenue":5.74,"enterpriseToEbitda":-37.48,"pegRatio":0,"ebitda":-69153000,"ebitdaMargin":-15.3,"freeCashflow":-164000,"operatingCashflow":-12451000,"totalDebt":83037000,"debtToEquity":24.2,"currentRatio":3.85,"returnOnAssets":-9.4,"returnOnEquity":-23.4,"analystRating":"1.1 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":9,"targetMeanPrice":95.11,"targetHighPrice":105,"targetLowPrice":88,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":3.1,"institutionHeldPercent":107.5,"sharesOutstanding":42557492,"floatShares":32259430,"sharesShort":5021787,"shortRatio":7.33,"shortPercentOfFloat":11.8,"epsTrailing":-1.59,"epsForward":2.89,"revenuePerShare":10.8,"bookValue":8.07,"officers":[{"age":null,"name":"Dr. Bobak R. Azamian M.D.","title":"Co-Founder, President, CEO & Chairman"},{"age":63,"name":"Mr. Jeffrey S.  Farrow CPA","title":"CFO & Chief Strategy Officer"},{"age":57,"name":"Dr. Seshadri  Neervannan Ph.D.","title":"Chief Operating Officer"},{"age":47,"name":"Mr. Aziz  Mottiwala M.B.A.","title":"Chief Commercial Officer"},{"age":46,"name":"Dr. Elizabeth  Yeu M.D.","title":"Chief Medical Officer"},{"age":null,"name":"Mr. David  Nakasone","title":"Head of Investor Relations"},{"age":47,"name":"Dr. Bryan  Wahl J.D., M.D.","title":"General Counsel & Corporate Secretary"},{"age":null,"name":"Ms. Adrienne  Kemp","title":"Senior Director of Corporate Communications"}],"industry":"Biotechnology","irWebsite":"","website":"https://tarsusrx.com","phone":"949 418 1801"}}